1. Introduction {#s0005}
===============

Modern clinical imaging, pathological ([@bb0575]) and genomic ([@bb0485]) data, support the evolving notion that neurodegenerative syndromes are best understood in terms of disrupted brain networking. Quantitative Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) provide compelling evidence of widespread network changes in neurodegenerations including Alzheimer\'s disease (AD) ([@bb0060]), Parkinson\'s disease (PD) ([@bb0175]), amyotrophic lateral sclerosis (ALS) ([@bb0370]) and frontotemporal dementia (FTD) ([@bb0050]). New therapeutic approaches based on network modulation are already in use for Parkinson\'s ([@bb0175]) and Alzheimer\'s Disease ([@bb0060]).

Notwithstanding, characterizing changes in brain networking in a clinical setting remains a challenge. Structural MR imaging can show changes in grey and white matter integrity ([@bb0515]) and functional imaging (fMRI) detects resting and activated states of metabolic activity. Neither modality can directly measure neuronal activity, however. Furthermore, as fMRI measurements can be confounded by vascular pathology and are limited by the requirements of the technology (including the need for the patient to remain supine) ([@bb0165]), the use of fMRI is limited in the neurodegenerations. There remains an urgent and unmet need for user-friendly, non-invasive technologies that can rapidly and reliably detect network alteration with high temporal and spatial resolution.

Here we review the biology of non-invasive electrophysiology-based measurements and outline the current state of the art in measurement of network dysfunction in the neurodegenerations. We explore the future potential of emerging electrophysiology-based technologies in providing enhanced temporal resolution, and in using source localization that improves spatial resolution to complement structural and functional imaging.

2. Methods {#s0010}
==========

2.1. Electroencephalography and magnetoencephalography {#s0015}
------------------------------------------------------

Quantitative EEG (qEEG) and magnetoencephalography (MEG) are increasingly recognized as useful non-invasive methods to measure cortical neurophysiological activity.

MEG and qEEG capture and digitise neuroelectromagnetic reflections of the synchronous generation of excitatory and inhibitory post-synaptic potentials in populations of underlying neurons. Both MEG and qEEG have excellent temporal but, until recently, limited spatial resolution. Several methods, collectively referred to as source localisation methods, have now been developed that enhance the spatial resolution of both EEG and MEG to that of using fMRI ([@bb0340]). This now allows for visualisation of brain activity at low cost, with high levels of both spatial and temporal resolution.

The physiologic basis of MEG and EEG differ. MEG sensors measure the magnetic field generated by the electrical flows in neuronal populations while EEG sensors measure the simultaneously-generated perpendicular electric field that passes through the space between the activity source and sensors ([@bb0090]). Due to volume conduction, EEG sensors also capture electrical currents propagated between the source and sensor in the conductive human head medium. This effect of volume conduction in EEG may make MEG a more reliable measure for deeper sources.

However, it must be noted that the potential advantage of MEG is reduced by the need for expensive superconductive systems ([@bb0565]) that significantly increase costs, limiting MEG\'s day-to-day application in clinical settings.

EEG and MEG both generate waveform data, where the x-axis represents time and the y-axis represents amplitude of electrical activity ([Box 1](#b0005){ref-type="boxed-text"}). Quantitative M/EEG involves the digitisation of these signals and quantitative analysis of their characteristics ([Fig. 1](#f0005){ref-type="fig"}). These analyses can be performed in time and frequency domains. Time domain analysis is the study of how brain activity changes over time ([@bb0385]) (for example at what time the intensity of neural activity peaks when performing a cognitive or motor task). Frequency domain analysis involves the use of Fourier transformation to decompose the recording into a combination of waves of different frequencies.Box 1Electrical and physiological characteristics defined in the context of EEG measurements.**Amplitude --** The size of the electrical charge in the cerebrospinal fluid produced by the summation of neuroelectric activity such as excitatory and inhibitory post synaptic potentials in cerebral cortical neurons, typically in microvolts (μV) ([@bb0080]).***Power --** A measure of the intensity of neuronal activity, proportional to the amplitude squared* ([@bb0080]).***Frequency --** The number of times a cycle of a wave repeats per unit time, measured in hertz (Hz)* ([@bb0080]).***Frequency bands --** Continuous ranges of frequencies for which measurements are grouped.**Oscillation --** Continuous, periodic neuronal activity, typically generated by feedback loops in neuronal networks* ([@bb0195])***Event-related potential (ERP) --** Electrical potential observed at the time that an event occurs, such as performing a motor or cognitive task or sensory stimulus* ([@bb0315], p.)*.**Event-related (de)synchronisation (ERD/ERS) --** Relative decrease or increase in the intensity of oscillatory activity in a frequency band, caused by an event such as performing a motor or cognitive task or sensory stimulus* ([@bb0405]).***Sensor-level** --Digitised M/EEG data analysed with respect to the position of the sensors on the scalp, providing poor spatial resolution.**Source-level** -- Digitised M/EEG data analysed using source localisation methods to determine the location of contributing sources in the brain, providing spatial resolution comparable to fMRI* ([@bb0340]).Alt-text: Box 1Fig. 1The transformation of a digitised EEG signal into a frequency power spectrum.Fig. 1

Typically, quantitative M/EEG signal frequencies are grouped into delta (0.5--3 Hz), theta (3--7 Hz), alpha (8--13 Hz), beta (14--30 Hz), and gamma (\>30 Hz) frequency bands ([@bb0045], p.). Oscillations in these different frequency bands have been attributed to different neuronal populations and brain activities ([@bb0195]) ([Box 1](#b0005){ref-type="boxed-text"}). This allows for investigation of brain activity in terms of the power of oscillating network activity at different frequencies, referred to as spectral EEG ([@bb0250]). Synchronous or time-correlated oscillations in different brain areas can also be used to infer functional connectivity between them ([@bb0510]). The frequencies of these bands are generally negatively correlated to their amplitude (i.e. lower frequency M\\EEG oscillations tend to have higher amplitude). Since amplitude is a reflection of the number of neurons contributing to a signal, lower frequency oscillations are attributed to synchronous activity of larger numbers of neurons ([@bb0405]).

These time and frequency domain network characteristics can be examined at rest ("resting-state") to investigate the resting activity of the brain ([Fig. 2](#f0010){ref-type="fig"}). M/EEG measures can also be captured during tasks such as cognition, sensation or movement, to measure the activity of brain regions contributing to the generation of that function ([Fig. 2](#f0010){ref-type="fig"}) ([@bb0145]; [@bb0500]). As tasks are underpinned by integration of various distinct neural networks, the corresponding neural signatures can be marked in the frequency domain, known as event-related (de)synchronisation (ERD/S), and/or the time domain, known as event-related potentials (ERPs) ([Box 1](#b0005){ref-type="boxed-text"}). Source localisation methods can subsequently be applied to identify the origin of these of the network components and any changes to their performance in disease. Each of these approaches allows for the study of different aspects of neural network function and can be combined to provide a well-rounded insight into the effects of disease pathology on brain network function.Fig. 2EEG signal processing avenues for resting-state and task-based paradigms, the quantitative measures obtained and sample interpretations in neurodegenerative disease.Fig. 2

2.2. Transcranial magnetic stimulation (TMS) {#s0020}
--------------------------------------------

TMS is the external application of a magnetic field to cortical neurons of interest, generating an electrical field around them. This electrical field will produce a charge across the membranes of the neurons in this area of the cortex, which will induce neuronal firing (e.g. the proliferation of an action potential along the axon) if of sufficient magnitude ([@bb0185]). Using an electromagnetic coil placed on the scalp this magnetic field can be delivered in focal pulses to the cortical area of interest. Therefore TMS has the major advantage of providing a method to stimulate the cortex that is both non-invasive and focal, unlike transcranial electrical stimulation ([@bb0130]).

TMS, coupled with surface electromyography (EMG) of muscles of interest can measure pyramidal tract function, anterior horn cell function and muscle activation ([Fig. 3](#f0015){ref-type="fig"}). By applying single stimulating pulses to the primary motor cortex, several commonly-used measures can be estimated, including: amplitude of the motor evoked potential (the EMG response to a stimulating pulse), the resting motor threshold (the minimum stimulation required to induce a standard motor evoked potential amplitude in 50% of electromyographic responses), cortical silent period (the period of interruption of voluntary muscle activity following stimulation of the corresponding motor cortical regions) and central motor conduction time (motor evoked potential latency less peripheral conduction time, measured by applying a TMS pulse at spinal level to the lower motor neurons innervating the target muscle) ([@bb0465]).Fig. 3Schematic of a single-pulse TMS procedure and the quantitative characteristics of the resulting motor evoked potential.Fig. 3

Paired-pulse TMS provides the use of a conditioning stimulus (CS) at different intervals in advance of the test stimulus (TS) from either the same coil or a separate coil placed above another cortical region, usually over the opposite hemisphere. This can be used to study changes in inhibitory and excitatory circuits modulating motor cortical function. These measures include changes in short- and long-interval intracortical inhibition, intracortical facilitation, short- and long-interhemispheric inhibition and interhemispheric facilitation. Each of these measures is used to interrogate regulatory inputs to the corticospinal tract ([@bb0170]).

3. Network dysfunction in neurodegeneration {#s0025}
===========================================

3.1. Resting state studies {#s0030}
--------------------------

"Resting state" EEG and MEG are used to explore brain activity and functional connectivity in the absence of specific tasks, although it must be acknowledged that the brain is continuously active with ongoing processing of both endogenous and exogenous information ([@bb0255]). Neurodegenerative conditions exhibit changes in resting state that correlate with underlying pathogenic processes, and there is emerging evidence that resting state EEG has considerable discriminatory value in neurodegeneration.

In ALS, resting state EEG can identify changes in the sensorimotor cortex, as exemplified by the presence of decreased alpha-band power ([@bb0320]; [@bb0370]; [@bb0480]). Alpha frequency oscillations over the sensorimotor cortex are attributed to the layer V pyramidal upper motor neurons ([@bb0235]), and as alpha power is known to decrease at movement onset ([@bb0405]) it is likely to represent the inactive state in these large cells. Loss of power in this band is therefore likely due to loss of cell bodies in this region, and possibly loss of inter-neuronal or thalamic control of the upper motor neurons at rest.

By contrast, broadband gamma power is increased over the motor cortex in PD, a finding that also differentiates PD from dystonia and essential tremor. This difference has been attributed to PD-related changes in the spiking of pyramidal cells ([@bb0085]) and may aid in differential diagnosis. Increase in basal ganglia-cortical beta power is also consistently identified in PD ([@bb0155]; [@bb0230]; [@bb0430]). The pathological effect of such excessive oscillations has been established using deep brain stimulation, with 5--20 Hz stimulation, but not 30-50 Hz stimulation, exacerbating bradykinesia ([@bb0230]).

Resting state EEG can also detect changes in brain connectivity. In ALS, resting state studies have identified increased connectivity throughout the cortex including increased median absolute coherence in theta and gamma band frequencies over prefrontal areas, accompanied by decreased gamma band synchrony for some prefrontal electrodes ([@bb0370]). Cortical gamma band oscillations have been linked to higher cognitive functions such as intermodal selective attention and perception ([@bb0195]), providing a quantitative measure for detecting early cognitive impairment in ALS. In PD, decreased frontoparietal connectivity coherence in alpha band is also associated with early executive impairment ([@bb0520]), suggesting that deterioration of frontoparietal attention networks contributes to executive dysfunction in PD.

Numerous studies have highlighted the utility of combining such resting state EEG activity and connectivity measures for differential diagnosis of neurodegenerations, particularly the dementias ([@bb0365]). For example, using temporal high beta, parietal theta and alpha and high beta power, a stepwise discrimination function can distinguish AD and FTD patients with 84.6% accuracy and is highly accurate in separating controls (100%) from FTD patients (84.6%) ([@bb0580]). With increase in computational power, this methodology has been enhanced, with training support vector machine classifiers using 25 EEG parameters capable of deciphering AD, PD, LBD and bvFTD with 100% specificity and sensitivity ([@bb0140]).

Such multidimensional biomarkers may also be enhanced by the addition of imaging and/or psychological task parameters to capture differences between broad, overlapping network pathologies. This has been demonstrated by logistic regression models combining cognitive task performance with delta and theta oscillatory activity which provide 93.3% accuracy when distinguishing AD from FTD ([@bb0310]).

EEG measures can also quantify responses to drug therapies, for example in PD patients L-DOPA is found to induce widespread reduction in cortical delta and alpha activity, considered to reflect an excitatory effect of dopamine neuromodulation ([@bb0020]), in addition to suppressing elevated beta oscillations in correlation with motor improvement ([@bb0360]). Such measures therefore have potential to provide objective, quantitative measures of drug effects on neurodegenerative pathology, enhancing the power of clinical trials. This potential has already been harnessed as a dose-finding pharmacodynamic biomarker in rodents, wherein dose-dependent increase in gamma band power in rats was used to estimate therapeutically relevant concentrations of a potential antidepressant drug in humans. This effect translated to similar increases in human resting-state EEG upon drug delivery ([@bb0475]).

Longitudinal resting-state M/EEG studies have been performed for a number of neurodegenerative conditions, but they are few in number. In AD, relative alpha and beta power is decreased, while relative theta and delta power increased longitudinally ([@bb0075]), with changes in relative theta power capable of distinguishing between different stages of dementia. This pattern is consistent across populations ([@bb0275]; [@bb0545]), demonstrating a global slowing in brain network signalling in AD.

Longitudinal increase in beta power has also been observed in PD, correlating with decline in Rey Auditory-Verbal Learning Test performance([@bb0065]), consistent with increasing delta power capturing progressive decline of specific cognitive networks. PD patients also show early impairment in brain network local efficiency as well as network decentralization which progress over time ([@bb0125]).

In ALS a single longitudinal resting-state study has been reported revealing widespread, progressive increase in median coherence in theta and low gamma band frequencies ([@bb0370]). This suggests that abnormal functional connectivity worsens throughout ALS pathology. Network activity may increase at disease onset and decline thereafter, and accordingly future studies will also require correlation with time from disease onset, and clinical stage of disease.

These studies demonstrate the ability of resting-state EEG to characterize and quantify neurodegenerations and their progression (see [Table 1](#t0005){ref-type="table"}). In all cases, to attribute the recorded changes to specific networks, source localisation will be required. Moreover, future longitudinal studies will require extensive validation across large groups of well-phenotyped patients.Table 1Neurophysiological biomarkers for and therapies in neurodegeneration.Table 1TechnologyMethodClinical applicationExampleDiseaseBiomarker/symptomReferenceEEG/MEGResting stateDifferential diagnosisFTD, AD, PDD, DLBMultiple([@bb0140]; [@bb0365]; [@bb0580])CT outcome measurePDBeta power([@bb0020]; [@bb0360])TMSPaired pulseDiagnostic biomarkerALSSICI([@bb0325]; [@bb0560])CT outcome measure[NCT02450552](NCT02450552){#ir0005}, [NCT02781454](NCT02781454){#ir0010}rTMSTo leg area of motor cortexTherapyMSSpasticity([@bb0350], [@bb0355]To leg area of motor cortexPDFreezing of gait([@bb0070]; [@bb0260])\
[NCT02850159](NCT02850159){#ir0015}To dorsolateral prefrontal cortex or motor cortexRefractory depression([@bb0300])To dorsolateral prefrontal cortexFTD, ADLanguage, memory, executive function([@bb0015]; [@bb0470])\
[NCT02621424](NCT02621424){#ir0020}DBSTo basal gangliaTherapyPDUPDRS score, mobility, activities of daily living, emotion, stigma, discomfort([@bb0110])To nucleus basalisADADAS-cog([@bb0270])[^2]

### 3.1.1. Source localization studies {#s0035}

Source-level studies using quantitative EEG can correlate pathological neuroelectric signals with anatomic locations. For example, in AD increases in delta band activity are localised to orbitofrontal and temporal cortices, while frontotemporal dementia (FTD) patients differ, exhibiting decreases in low alpha band activity in these areas ([@bb0380]). By contrast, reduced alpha activity in occipital sources and widespread increase in delta sources is revealed by source localisation in PD with and without cognitive impairment ([@bb0020]).

Source localisation can also be used to enhance the spatial resolution of connectivity measures. For example, localised lagged linear connectivity in alpha band has been found to discriminate AD, Dementia with Lewy Bodies and PD dementia from controls with areas under the ROC curves of 0.84, 0.78 and 0.75 respectively. Source localisation of EEG resting state connectivity in ALS patients has also revealed increased functional connectivity between the posterior parietal cortices (PPCs) and between the PPC and the motor cortex, dorsolateral, dorsomedial and ventrolateral prefrontal corticess. Source analysis also reveals increases in general connectivity of the anterior and posterior cingulate cortices, frontoinsular cortex, anterior insular cortex and dorsomedial and ventrolateral prefrontal cortices to other brain areas in ALS ([@bb0220]). Source localised EEG measures therefore provide objective evidence that ALS and FTD have overlapping pathologies ([@bb0415]), with cognitive networks disrupted in FTD, such as the frontoparietal attention networks ([@bb0590]), also dysfunctioning in ALS, while central and parietal activity known to be abnormal in ALS ([@bb0370]), is found to distinguish FTD from AD ([@bb0380]).

3.2. Activation studies {#s0040}
-----------------------

### 3.2.1. Event-related M/EEG {#s0045}

Network performance can also be quantified by measuring frequency or time domain characteristics of M/EEG signals generated by the performance of motor ([@bb0500]), sensory ([@bb0345]) or cognitive ([@bb0315]) tasks designed to activate target neural networks.

#### 3.2.1.1. Motor tasks {#s0050}

M/EEG can provide quantitative measures of motor network performance during movement. Movements are preceded by decrease in alpha and beta band oscillation power in the primary motor cortex. This is referred to as event-related desynchronisation (ERD). ERD is interpreted as an electrophysiological correlate of increasing activity in cortical areas involved in the movement ([@bb0405]). ERD is therefore used to quantitatively measure motor cortex dysfunction in disease. For example, in multiple sclerosis (MS), latency of ERD correlates with structural MRI T1 lesion volume and T2 lesion load ([@bb0290]), while in PD, ERD begins closer to movement onset ([@bb0095]), particularly in the affected hemisphere ([@bb0100]). This difference is partially corrected by L-DOPA ([@bb0105]). By contrast, ERD is conserved in the upper motor neuron syndrome of Primary Lateral Sclerosis, despite the presence of decreased amplitude in movement-related potentials ([@bb0025]), suggesting that changes in ERD may quantify dysfunction of cells that regulate the primary motor cortex or non-upper motor neuron cells that receive thalamo-cortical input.

Following ERD, in the first second after movement ends, increased beta-band oscillations are recorded in the primary motor cortex, most prominent over the contralateral sensorimotor cortex. This is referred to as beta event related synchronisation (ERS) and is attributed to a shift of the primary motor cortex from activation back to an inactive state ([@bb0405]). Change in post-movement ERS has also been documented in MS, PD and ALS, providing additional quantitative measurement of motor cortex dysfunction. In MS, the latency of the ERS peak is significantly later and correlates to longer information processing speeds ([@bb0040]), while in both ALS ([@bb0455]) and PD ([@bb0120]) ERS is reduced, even during dopaminergic treatment ([@bb0410]). In ALS, negative correlations between ERS and measures of structural (subcortical frontal apparent diffusion coefficient) and functional (MEP to compound muscle action potential ratio) corticospinal tract integrity have also been reported ([@bb0455]). Increase in ERS may therefore represent a measure of impaired inhibition or excess activity of upper motor neurons.

The time domain characteristics of M/EEG can provide additional neurophysiological correlates of motor tasks, known as movement related potentials (MRPs) ([@bb0315]). Two major MRPs are elicited during motor planning. These are the Bereitschaftspotential (BP) ([@bb0500]) and the contingent negative variation ([@bb0460]), providing measures of contributing motor preparatory and planning networks\' function.

Source localisation has attributed the early BP to the supplementary motor area and premotor cortex bilaterally, followed by activity in the contralateral premotor and primary motor cortices ([@bb0500]). In PD, BP peak amplitude is not affected in patients compared with controls, but the early part of the of the waveform is attenuated ([@bb0115]). Decrease in peak amplitude does, however, correlate with increasing disease severity ([@bb0395]). This may reflect inadequate activation of the supplementary motor area by the basal ganglia ([@bb0115]) or supplementary motor area pathology in PD. Comparable findings in ALS, wherein BP amplitude is inversely correlated with spasticity ([@bb0570]), demonstrate an overlap in the network pathology of these two neurodegenerations in the basal ganglia and/or the supplementary motor area. Such clinical correlation also points to a utility of these measures as prognostic biomarkers.

The contingent negative variation (CNV) has been localised in part to the premotor cortex and supplementary motor area ([@bb0205]); however, CNV also represents prefrontal network activity in the orbitofrontal, mesial and dorsolateral prefrontal cortices, unlike the BP ([@bb0215]), therefore capturing additional motor preparatory network components. Mean amplitude of CNV is increased in ALS ([@bb0190]), decreased in PD ([@bb0445]) and MS ([@bb0440]; [@bb0530]) and unaffected in Alzheimer\'s disease (AD) ([@bb0540]). The discrepancy between ALS-related BP and CNV abnormalities suggests that prefrontal network decline makes an important contribution to changes in this ERP, consistent with the now-well established cognitive component of ALS pathology ([@bb0415]). Furthermore, decrease in CNV amplitude over the parietal cortex in MS correlates with neuropsychological test performance ([@bb0530]). This suggests that CNV also captures parietal network components pertaining to movement preparation and planning.

Localisation analyses have yet to identify the source(s) causing the disease-related abnormalities in MRPs. Such analyses are likely to reveal which cognitive and motor network components contribute to MRP changes in each of these neurodegenerations, highlighting any network overlap and potentially providing distinguishing biomarkers.

#### 3.2.1.2. Sensory tasks {#s0055}

Somatosensory ERPs, commonly referred to as SEP or SSEP, can provide information about the involvement of primary somatosensory cortex and its inputs in neurodegenerative diseases. For example, dysfunction of thalamocortical neurons of the ascending somatosensory tracts can be shown in ALS and HD. N20, an ERP generated by median nerve stimulation, is attributed to the initial primary somatosensory cortex in somatosensation ([@bb0035]). N20 has increased latency in HD ([@bb0005]) and ALS ([@bb0585]) patients, indicating pathological delay in transmission of stimuli to the cortex. In ALS, N20 latency increase occurs in the presence of normal peripheral conduction time, while in HD P15 latency (attributed to the brainstem ([@bb0345]) is normal ([@bb0240]), indicating that these impairments represent dysfunction of thalamocortical neurons of the ascending somatosensory tracts in ALS and HD pathology. Decrease in N20 amplitude also correlates to disease duration in ALS ([@bb0210]), which may reflect spread of pathology from the motor cortex to the primary somatosensory with disease progression.

#### 3.2.1.3. Cognitive tasks {#s0060}

A variety of different cognitive ERPs and ERP subcomponents have been used to objectively assess performance of different cognitive tasks in neurodegeneration, including P3 and mismatch negativity.

P3 is a positive peak seen in the average ERP 200-500 ms after an infrequent 'deviant' stimulus is delivered in a train of attended 'standard' stimuli, known as an oddball paradigm. It has been associated with inhibition of cortical networks to facilitate delivery of attention stimuli in the aftermath of an alerting signal ([@bb0425]), and therefore can be used to quantify attention network impairment in neurodegenerative disease. For example, as P3 latency is longer for more complex stimulus evaluation and decision making tasks ([@bb0425]), P3 latency is used to test the speed of attentional processes.

P3 latency is increased in MCI ([@bb0280]), AD ([@bb0400]), ALS ([@bb0160]) and PD ([@bb0525]) and is predicted by lesion load in MS ([@bb0265]). P3 has been shown to be delayed or absent in 100% of a small group of cognitively impaired ALS patients ([@bb0435]) and is inversely correlated to performance in cognitive tasks globally, as well as specifically for language and attention in AD ([@bb0285]).

Mismatch negativity (MMN, also referred to as N2a) is another cognitive ERP generated by oddball paradigms, however unlike P3, MMN has the advantage that it does not require active patient participation. MMN is a negative peak at approximately 200 ms post-stimulus seen when the average ERP following a standard stimulus is subtracted from the average response to deviant stimuli. MMN is a physiological measure of working sensory memory, involuntary attention switching and sensory accuracy, therefore capturing both cognitive and sensory networks ([@bb0145]).

MMN shows increased average delay correlating to response-inhibition task performance in ALS ([@bb0225]), while in both PD and MS MMN is reduced in cognitively impaired patients compared to those without cognitive impairment ([@bb0055]; [@bb0245]). Reduced MMN amplitude is also reported in MCI and AD as reviewed by [@bb0200]. Such cognitive correlations to MMN impairment point to the potential of MMN an additional quantitative measure of network dysfunction in neurodegeneration.

Few longitudinal studies of change in cognitive ERPs have been published, although in AD the P3 latency has repeatedly been shown to increase over time ([@bb0030]), with latency increase being more substantial in those with greater cognitive decline ([@bb0505]). In ALS, correlation studies have found that P3 amplitude is related to disease duration ([@bb0550]) and that P3a latency correlates to months from disease onset and symptoms severity ([@bb0450]), consistent with progressive network decline with disease progression.

Source analysis of MMN and P3 can distinguish different degenerations with similar sensor-level ERP changes and provide more information about neurodegenerative pathology. To date however, few studies have utilised source analysis to determine the exact location of the networks producing such abnormalities, and the spatial resolution of existing findings remains to be definitively established.

### 3.2.2. Transcranial magnetic stimulation {#s0065}

TMS has been established for three decades as a useful tool that interrogates cortical and potentially subcortical motor networks ([@bb0465]). TMS can interrogate motor cortical excitability and has demonstrated that hyperexcitability is a feature of feature of ALS, PD and HD, although the excitable characteristics of these conditions differ (discussed below).

Resting motor threshold (RMT), a TMS-based measure of upper motor neuron excitability, is decreased in ALS ([@bb0180]; [@bb0560]) and AD ([@bb0305]) but not in PD ([@bb0375]) or HD ([@bb0010]). Conversely, PD patients show greater motor evoked potential (MEP) amplitudes at low stimulus intensity ([@bb0295]) and an inverse correlation between motor impairment and RMT ([@bb0390]).

TMS can also interrogate the function of intracortical circuits regulating the corticospinal tract. SICI is a measure of the increase in muscle response to cortical magnetic stimulation due to a preceding conditioning stimulus from the same coil and is a measure of inhibitory interneuron function ([@bb0595]). Huntington\'s disease (HD), AD, PD and ALS each exhibit reduced short intracortical inhibition (SICI) ([@bb0010]; [@bb0180]; [@bb0305]; [@bb0375]; [@bb0420]; [@bb0560]). This suggests that reduced inhibitory input to upper motor neurons contributes to corticospinal tract hyperexcitability. SICI may also capture dysfunction of dopaminergic circuitry. Dopaminergic drugs can increase SICI, while anti-dopaminergic drugs decrease SICI ([@bb0600]). Furthermore, in PD, dopaminergic drugs and BG deep brain stimulation can partially rectify reduced SICI ([@bb0375]; [@bb0420]). In AD, SICI decrease correlates with cognitive decline, and can be partially counteracted by donepezil ([@bb0305]), also suggesting some cholinergic input to the SICI-generating circuitry.

Intracortical facilitation (ICF) is the increase in muscle response to cortical magnetic stimulation due to a preceding conditioning stimulus from the same coil. The interstimulus interval values giving rise to ICF are higher than those for SICI. ICF is increased in HD ([@bb0010]), ALS ([@bb0180]; [@bb0560]) and PD ([@bb0375]). The circuitry underlying ICF is relatively poorly understood, although novel investigation using the threshold tracking method indicates that short and long ICF measures of different circuitry exist, which differ in underlying circuitry from each other and that of SICI ([@bb0535]). Pharmacological studies suggest ICF also involves GABAergic and dopaminergic circuitry ([@bb0600]). Consistent with this hypothesis, the ICF increase in PD can be partially counteracted by dopaminergic treatment ([@bb0375]).

Both increased ICF and decreased/absent SICI have been reported in three pre-symptomatic SOD-1 mutant carriers who later developed ALS ([@bb0560]), while increased RMT has been found in preclinical and very early HD ([@bb0495]).

These observations point to the potential utility of TMS-based biomarkers of early neurodegeneration (see [Table 1](#t0005){ref-type="table"}).

Longitudinal TMS studies in ALS show decreases in MEP amplitude and increases in RMT ([@bb0135]) and cortical silent period ([@bb0330]) with progression of the disease. SICI also correlates with measures of disease progression (compound muscle action potential, strength-duration time constant and neurophysiologic index) ([@bb0555]) in TT-TMS studies. This is consistent with early excess excitation which later declines with degeneration of the motor system, leading to loss of function. In keeping with this hypothesis, RMT is decreased in patients who do not exhibit a weakness, wasting or upper motor neuron symptoms, but increased in those with lower and upper motor neuron symptoms ([@bb0335]).

4. Therapeutic approaches using network modulation {#s0070}
==================================================

4.1. Electrical and magnetic stimulation {#s0075}
----------------------------------------

Given the extensive literature of network dysfunction across the neurodegenerations, the neurophysiological modulation of these abnormalities presents a potential therapeutic target for these disorders (see [Table 1](#t0005){ref-type="table"}). In addition to the utility of deep brain stimulation in artificially maintaining basal ganglia function in PD, it is now known to have a separate therapeutic effect on the disease, improving motor function and emotional well-being compared to medication alone ([@bb0110]). In a small study of AD patients stimulation of the nucleus basalis of Meynert stabilises or improves cognition over a year ([@bb0270]), illustrating the potential utility of deep brain stimulation in other brain network disorders.

TMS can also be used to deliver trains of magnetic stimuli to any part of the cortex, typically at least once per second, in order to alter network activity. This is known as repetitive TMS (rTMS) and has recently been approved as a therapy for treatment-resistant depression ([@bb0150]). RTMS has now been found to have therapeutic effects in a number of neurodegenerative diseases. Such effects include reduction of spasticity in MS ([@bb0350], [@bb0355]), improved cognition and functionality in FTD ([@bb0015]), improved cognition and reduced cognitive decline in AD ([@bb0470]) and reduced freezing of gait in PD ([@bb0260]). Furthermore, six out of seven studies investigating the effects of rTMS on refractory depression in PD identified significant improvement ([@bb0300]).

Some such effects are already being brought towards clinical practice. For example, rTMS is currently being investigated as a network modulating therapy for dementia in MCI or AD ([NCT02621424](NCT02621424){#ir0025}) and spasticity in MS ([NCT02747914](NCT02747914){#ir0030}, [NCT01106365](NCT01106365){#ir0035}). A completed trial of rTMS in PD ([NCT03219892](NCT03219892){#ir0040}) has also identified a significant therapeutic effect on freezing of gait as well as ambulatory and motor function ([@bb0070]).

4.2. Pharmacological network modulation {#s0080}
---------------------------------------

Pharmacological intervention to rectify network dysfunction is being investigated in a number of neurodegenerations. In addition to the correction of neurophysiological measures by existing drug therapies ([@bb0105]; [@bb0305]; [@bb0375]), novel neurotherapeutics are being investigated on the basis of their network modulating properties. In ALS, a recent retigabine trial has used decrease in SICI as a recruitment criterion ([NCT02450552](NCT02450552){#ir0045}) while a trial of mexiletine ([NCT02781454](NCT02781454){#ir0050}) is now using change in RMT and SICI as primary and secondary outcome measures respectively. Resting-state EEG was also utilised as a secondary outcome measure in testing the nutritional aid Souvenaid as a therapy in AD, with change in delta band functional connectivity showing improved trajectory ([@bb0490]).

A combination of multimodal evoked potentials was also used an outcome measure in a phase III trial ([NCT01765361](NCT01765361){#ir0055}) of the recently approved drug ocrelizumab for MS.

These early studies point to a move towards therapies based on modulation of network dysfunction, allowing for earlier, and possibly presymptomatic intervention based on early changes in physiological measures.

5. Conclusion {#s0085}
=============

Neurophysiological recording and neuro-electric/−magnetic signal analysis can characterize patterned changes of network function in neurodegeneration, opening up opportunities for novel biomarkers of disease progression. The attractive properties of neurophysiological measurements have often been overlooked in the past. The development of focal TMS and source localisation of M/EEG signals can now provide direct measurements of network activity with high spatiotemporal resolution. These new developments provide additional opportunities for neurophysiology-based signal analysis as an additional investigational tool in neurodegeneration.

Directly quantifying network activity can be used to objectively identify neurodegeneration without relying on subjectively-measured symptoms which manifest from network dysfunction. This can allow for earlier and potentially presymptomatic intervention, providing greater probability of therapeutic success. Such measures are already being harnessed in clinical trials, however their full potential as outcome measures is still underexploited.

Neuroelectric signalling studies have already sufficiently demonstrated the importance of network dysfunction in neurodegeneration to drive development of network modulating stimuli and drugs as the therapeutic options and suggests that other pharmacologic agents that act to modulate network dysfunction are likely to be of therapeutic benefit. Additional studies are now required to fully exploit the potential of M/EEG and TMS across the range of neurodegenerations, including additional processing and source localization that can discriminate different disease subtypes.
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